ClinicalTrials.gg
Not yet recruitingNCT04569227Updated Oct 21, 2026

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

A Phase 2 interventional study of EC-18 and Placebo in Covid19 Pneumonia, sponsored by Enzychem Lifesciences Corporation. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Enzychem Lifesciences Corporation · Phase 2, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now Not yet recruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment
747th of 1,322
60 · median 92
Started
2026
with 23 others
Phase 2
350 of 1,860
15 open now
Primary completion
2027-12
later than 158 of 208 live
Registered
707th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 747th largest by planned enrollment of the 1,322 interventional ones that give a count, is one of 24 that started in 2026, is one of 350 in phase 2, reaches primary completion later than 158 of the 208 other live ones, and was the 707th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19

03

Conditions studied

  • Covid19 Pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following criteria:

    1. Male or female ≥18 years old
    2. Subjects with confirmed diagnoses of pneumonia caused by COVID-19 from:

      • RT-PCR or Abbott ID Now COVID-19 test
      • Chest X-ray or computed tomography (CT) scan (findings of the increased opacity on a chest X-ray, ground-glass opacity indicative of pneumonia on CT, opinion on consolidation, etc.)
    3. Those who can tolerate oral administration
    4. Those who do not need oxygen therapy or only need low-flow oxygen (at least 4L/min) but not requiring high-flow oxygen (higher than 4-6L/min) or non-invasive/invasive ventilation primarily according to the WHO guidance
    5. Those who are planned to be hospitalized or who are just hospitalized
    6. Those who have been fully explained about this clinical study and have voluntarily agreed to participate in this clinical study by signing the form (ICF)

Exclusion criteria

Exclusion Criteria:

  • Subjects cannot participate in this clinical study if they satisfy any of the following criteria:

    1. Those who are diagnosed with viral pneumonia caused by other than COVID-19 or bacterial pneumonia during the screening
    2. Patients with severe pneumonia according to the WHO guidance

      • Have fever or signs of respiratory infections and
      • Satisfy any one of the following conditions: Respiratory rate > 30 breaths/min, severe respiratory distress, or room air oxygen saturation (SpO2) ≤ 93%
    3. Patients with ARDS according to the WHO guidance
    4. Those who have past medical histories described below:

      • Those who have medical histories of (HIV), acquired immunodeficiency syndrome (AIDS), or or C viral infection
      • Those who cannot have a CT test done due to allergy to contrast agents, etc.
    5. Those who have comorbidities/symptoms described below:

      • Those who have a history or evidence of another condition that may pose risks to patient safety or interfere with the study procedures, assessments or completion as determined by the investigator
      • Those who have moderate or severe renal impairment ( \< 60 mL/min/1.73 m2)
      • Those who have moderate or severe hepatic impairment ( B or C, respectively)
    6. Patients who are being treated with or other for asthma or diseases at the entry of study are excluded, because these drugs counteract the action mechanism of EC-18 (PLAG).
    7. Those who have any abnormalities in laboratory tests described below:

      • Clinically significant liver function abnormality (Satisfy any one or more of the following):
      • Serum (ALT) ≥ (ULN) × 2.5
      • Serum aspartate aminotransferase (AST) ≥ ULN × 2.5
      • Serum total ≥ ULN × 2.5
    8. Patients with uncontrolled diabetes ( > 7.0%)
    9. Those who have reactions to the IP and its components
    10. Those who satisfy any of the descriptions below:

      • Pregnant or breastfeeding female subjects
      • Those who are planning on pregnancy or not using accepted measures during the clinical study
    11. Those who have participated in other clinical studies to receive IPs or apply medical devices within 1 month from the time of obtaining the
    12. Those who are considered to be ineligible to participate in the clinical study or have difficulty conducting this clinical study by the investigator
    13. Those subjects with \< lower limit of normal (LLN) for males and females
    14. Those subjects with a count \< LLN
    15. Those subjects with a WBC \< LLN
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active EC-18

    Drug: EC-18

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients alive and free of respiratory failure through at Day 28

    Time frame: 28 days

Secondary outcomes

  1. Probability of progression of mild pneumonia patients to severe pneumonia or ARDS within 28 days

    Time frame: 28 days

  2. Assessment of all-cause mortality

    Time frame: 28 days

  3. Respiratory failure defined based on resource utilization requiring at least 1 of the following:

    * Endotracheal intubation and mechanical ventilation * Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \> 20L/min with a fraction of delivered oxygen ≥ 0.5) * Non-invasive positive pressure ventilation * Extracorporeal membrane oxygenation

    Time frame: 28 days

  4. Proportion of patients alive and free of invasive mechanical ventilation at a pre-specified timepoint

    Time frame: 28 days

  5. Proportion of patients alive and discharged from the hospital at a pre-specified timepoint

    Time frame: 28 days

  6. Lengths of ICU stay

    Time frame: 28 days

  7. Lengths of alive and respiratory failure-free days

    Time frame: 28 days

  8. Proportion of patients with objective measures of improvement (returning to room air) at time points (days 7, 14, and 28)

    Time frame: 7, 14, and 28 days

  9. Confirmation of changes in subject's subjective clinical symptoms (e.g., patient questionnaire)

    o Check for changes in symptoms on a daily basis for 28 days compared to the baseline at day 1

    Time frame: 28 days

07

Study locations

2 sites
  • Lincoln Medical Center
    The Bronx, New York 10451, United States
    • Maryanne Guerrero · Contact
    • Nail Cemalovic, MD · Principal investigator
  • Kent County Memorial Hospital
    Warwick, Rhode Island 02886, United States
    • Joni Harris · Contact
    • Hadeel Zainah, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 12 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Apr 2021 → Dec 2026, primary completion Sep 2021 → Dec 2027 and completion Nov 2021 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2020
First posted
Sep 29, 2020
StartEst.
Dec 30, 2026was Apr 2021
Primary completionEst.
Dec 30, 2027was Sep 2021
CompletionEst.
Jan 1, 2028was Nov 2021
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Withdrawn→Not yet recruiting Reason for stopping removed
changed Oct 21, 2026
Start date
Apr 30, 2021→Dec 30, 2026
Oct 21, 2026
Primary completion
Sep 2021→Dec 30, 2027
Oct 21, 2026
Study completion
Nov 2021→Jan 1, 2028
Oct 21, 2026
Enrollment
0 (actual)→60 (estimated)
Oct 21, 2026
Contact
Study contact now listed: added d•••@enzychem.com · •••3804; added •••6976. See the current contact
Oct 21, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Lincoln Medical Center · The Bronx, United StatesContact added (no phone or email listed)Contact added (no phone or email listed)
  • Kent County Memorial Hospital · Warwick, United StatesContact added (no phone or email listed)Contact added (no phone or email listed)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Withdrawn→Not yet recruiting
    Why stopped Reason for stopping removed
    Start date Apr 30, 2021→Dec 30, 2026
    Primary completion Sep 2021→Dec 30, 2027
    Study completion Nov 2021→Jan 1, 2028
    Enrollment 0 (actual)→60 (estimated)
    Contact Study contact now listed: added d•••@enzychem.com · •••3804; added •••6976. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Lincoln Medical Center · The Bronx, United StatesContact added (no phone or email listed)Contact added (no phone or email listed)
    • Kent County Memorial Hospital · Warwick, United StatesContact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04569227
Lead sponsor
Enzychem Lifesciences Corporation
Responsible party
Sponsor
First posted
Sep 29, 2020
Start date
Dec 30, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Dongsung Kim, Ph.D.
Contact
dongsung.kim@enzychem.com
2016763804
Ted Kim, M.B.A.
Contact
2013216976

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosedipimod

Start the discussion